SEC Form 4 · accession 0001209191-15-075194
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Ruffo
Officer — Chief Financial Officer
Period of report
Oct 13, 2015
Accepted (ET)
Oct 13, 2015 · 1:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 13, 2015 | C | 7,478 | — | A | 137,912 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF2 | — | Oct 13, 2015 | C | 20,000 | D | — | — | Common Stock | 5,797 | 0 | D |
| Series B Preferred StockF2 | — | Oct 13, 2015 | C | 5,802 | D | — | — | Common Stock | 1,681 | 0 | D |
Explanation of responses
- F1The total represents shares received upon conversion of shares of Series A Preferred Stock and Series B Preferred Stock.
- F2Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.